The European Medicines Agency is inviting stakeholder feedback on a proposal to update its 10-year-old guidance on developing drugs for treating major depressive disorder (MDD).
The proposed revisions aim to address, among other things, the emergence of new rapid acting antidepressants and the repurposing of...








